Literature DB >> 34648072

Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress.

Michelle T Lee1,2, Dhruv Mahtta1,2,3, Louis Dlouhy3, Hunaina Shahab4, Mahmoud Al Rifai3, Salim S Virani5,6,7,8.   

Abstract

PURPOSE OF REVIEW: This review highlights select studies presented at the virtual 2021 European Society of Cardiology (ESC) Congress. RECENT
FINDINGS: Reviewed studies assess single photon emission computed tomography, positron emission tomography, magnetic resonance imaging in coronary artery disease (PACIFIC-II); empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); dapagliflozin in chronic heart failure (DAPA-HF); proprotein convertase subtilisin/kexin type 9 inhibitor and its lipid lowering effects (NATURE-PCSK9); fixed-dose combination therapies with or without aspirin in primary prevention; overview of contrasting results between REDUCE-IT versus STRENGTH trials; Quadruple UltrA-low-dose tReaTment for hypertension (QUARTET); evolocumab and changes in plaque composition on optical coherence tomography (HUYGENS); and low-dose rivaroxaban during the acute phase of acute coronary syndrome (H-REPLACE). Research presented at the 2021 ESC Congress shows promise in reducing burden of cardiovascular disease and reinforces the value of cardiovascular disease prevention.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  Aspirin; Atherosclerotic cardiovascular disease; Cardiovascular prevention; Dapagliflozin; Empagliflozin; Heart failure

Mesh:

Substances:

Year:  2021        PMID: 34648072     DOI: 10.1007/s11883-021-00975-8

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  3 in total

1.  Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study.

Authors:  Francesco Prati; Enrico Romagnoli; Laura Gatto; Alessio La Manna; Francesco Burzotta; Yukio Ozaki; Valeria Marco; Alberto Boi; Massimo Fineschi; Franco Fabbiocchi; Nevio Taglieri; Giampaolo Niccoli; Carlo Trani; Francesco Versaci; Giuseppe Calligaris; Gianni Ruscica; Alessandro Di Giorgio; Rocco Vergallo; Mario Albertucci; Giuseppe Biondi-Zoccai; Corrado Tamburino; Filippo Crea; Fernando Alfonso; Eloisa Arbustini
Journal:  Eur Heart J       Date:  2020-01-14       Impact factor: 29.983

2.  Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.

Authors:  Philip Joseph; Gholamreza Roshandel; Peggy Gao; Prem Pais; Eva Lonn; Denis Xavier; Alvaro Avezum; Jun Zhu; Lisheng Liu; Karen Sliwa; Habib Gamra; Shrikant I Bangdiwala; Koon Teo; Rafael Diaz; Antonio Dans; Patricio Lopez-Jaramillo; Dorairaj Prabhakaran; Jose Maria Castellano; Valentin Fuster; Anthony Rodgers; Mark D Huffman; Jackie Bosch; Gilles R Dagenais; Reza Malekzadeh; Salim Yusuf
Journal:  Lancet       Date:  2021-08-29       Impact factor: 79.321

Review 3.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  Circulation       Date:  2019-03-17       Impact factor: 29.690

  3 in total
  2 in total

Review 1.  Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American College of Cardiology Scientific Sessions.

Authors:  Melody Hermel; Stacy Tsai; Luis Dlouhy; Anupama B K; Jamal S Rana; Sourbha S Dani; Salim S Virani
Journal:  Curr Atheroscler Rep       Date:  2022-05-28       Impact factor: 5.967

Review 2.  Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions.

Authors:  Michelle T Lee; Jerin George; Hunaina Shahab; Melody Hermel; Jamal S Rana; Salim S Virani
Journal:  Curr Atheroscler Rep       Date:  2022-01-24       Impact factor: 5.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.